Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22326722 | 0.79 | PI4KA (0.37) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL10120458 | 0.76 | PI4KA (0.39) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL23679750 | 0.76 | PI4KA (0.35) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL275109 | 0.75 | XDH (0.32) | — | |
| SCHEMBL21539219 | 0.73 | PI4KA (0.33) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL31329908 | 0.72 | HRH4 (0.33) | ABL1KDRMAP4K4 | |
| SCHEMBL21636967 | 0.72 | TLR7 (0.39) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL21943279 | 0.72 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL23476726 | 0.72 | ENPP1 (0.40) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL24075457 | 0.72 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118767697-B | Porous membrane for asymmetric all-vanadium redox flow battery and preparation method thereof | 杭州德海艾科能源科技有限公司 | 2024-11-19 | — | — | CN | claimed |
| CN-118767697-A | Porous membrane for asymmetric all-vanadium redox flow battery and preparation method thereof | 杭州德海艾科能源科技有限公司 | 2024-10-15 | — | — | CN | claimed |
| US-12516065-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4593836-A2 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | Board of Regents, The University of Texas System (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250243209-A1 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-07-31 | — | — | US | disclosed |
| CN-119894513-A | Heterocycles as modulators of NSD activity | 德州大学系统董事会 | 2025-04-25 | — | — | CN | disclosed |
| CN-118767697-B | Porous membrane for asymmetric all-vanadium redox flow battery and preparation method thereof | 杭州德海艾科能源科技有限公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-118767697-A | Porous membrane for asymmetric all-vanadium redox flow battery and preparation method thereof | 杭州德海艾科能源科技有限公司 | 2024-10-15 | — | — | CN | disclosed |
| US-12102648-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20240228498-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| CN-104086553-A | Method for preparing 7-bromoimidazo[2,1-f][1,2,4]triazin-4-amine | PHARMABLOCK NANJING R & D CO LTD | 2014-10-08 | — | — | CN | disclosed |
| CN-104086553-A | Method for preparing 7-bromoimidazo[2,1-f][1,2,4]triazin-4-amine | PHARMABLOCK NANJING R & D CO LTD | 2014-10-08 | — | — | CN | disclosed |
| WO-2014035140-A2 | COMPOUNDS AND COMPOSITIONS FOR MODULATING HISTONE METHYLTRANSFERASE ACTIVITY | KAINOS MEDICINE, INC. (KR) | 2014-03-06 | — | — | WO | disclosed |
| US-8455451-B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455451-B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| WO-2012039791-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012039787-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NSUN2, CDA | PI4KA 153/4885PI4K2B 192/4885PI4K2A 103/4885 |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3R5 | PI4KA 5/4885PI4K2B 13/4885PI4K2A 14/4885 |
| US-20240228498-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | PI4KA 13/4885PI4K2B 20/4885PI4K2A 27/4885 |
| US-12102648-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | PI4KA 3661/4885PI4K2B 3223/4885PI4K2A 3497/4885 |
| US-20250243209-A1 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | NSD3, NCOA1, NR1D1 | PI4KA 4249/4885PI4K2B 4125/4885PI4K2A 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.